Visit Website →
← Back to blog

TGA Peptide Rules in Australia: What Applies in 2026

October 24, 2026
TGA Peptide Rules in Australia: What Applies in 2026

In Australia, peptide products are regulated as therapeutic goods. A peptide is either approved and on the Australian Register of Therapeutic Goods (ARTG), or it is unapproved, and unapproved products cannot lawfully be advertised, imported for stock, manufactured or supplied for therapeutic use. Many of the best-known names, including BPC-157, TB-500, CJC-1295 and retatrutide, are unapproved. This guide sets out the rules as they stand in October 2026, who they affect and where laboratory research sits.

Peptasticlabs
Source Research Peptides With Clarity
Explore Peptastic Labs’ independently tested research-grade peptides, with HPLC purity verification and Certificates of Analysis available on request.
View the research catalogue

TL;DR

  • All peptides are regulated as therapeutic goods in Australia. Many popular ones are unapproved and have not been assessed by the TGA for safety, quality or effectiveness.
  • BPC-157 has been a Schedule 4 (prescription only) substance since June 2024. Advertising prescription-only medicines to the public is prohibited.
  • The Personal Importation Scheme requires a valid Australian prescription and does not allow importing unapproved goods for stock or supply.
  • A "research use only" label does not change regulatory status if a product is used therapeutically.
  • The TGA lists unapproved peptides as a priority area in 2026 and works with the Australian Border Force (ABF) on seizures.

Table of Contents

How the TGA classifies peptides

Peptides are short chains of amino acids. Some are established medicines, such as those used in diabetes and weight management. Others are research compounds that have never been through clinical trials. The TGA does not regulate by the word "peptide". It regulates by use and claim: if a product is presented or used to treat, prevent, diagnose or alter a physiological process in people, it is a therapeutic good.

That gives two broad groups:

CategoryStatusTypical access
Approved, on the ARTGAssessed for safety, quality and efficacyPrescription from an Australian practitioner, supplied by a pharmacy
UnapprovedNot assessed by the TGAOnly through the Special Access Scheme, Authorised Prescriber pathway or clinical trials

The Aesthetic Medical Practitioner summary of the TGA's warning notes that unapproved goods, including many peptides, can be accessed only through pathways such as the Special Access Scheme (SAS) or Authorised Prescriber (AP). A consumer cannot open either pathway on their own. A treating practitioner applies.

Scheduling: BPC-157 and prescription-only status

The Poisons Standard sets who may supply a substance. As of June 2024, BPC-157 is a Schedule 4 substance. Supply is restricted to people with a valid prescription from an authorised practitioner, and possessing it without authority is unlawful.

Two consequences follow:

  1. Capsules, sprays or injectables sold to the public as BPC-157 are not a legal over-the-counter product.
  2. Advertising a prescription-only medicine to the public is prohibited, whatever the channel.

The TGA's guidance for health practitioners explains why doctors are cautious. Most research peptides have no human safety data, so the risk-benefit profile is unknown and responsibility sits with the prescriber.

Personal importation: what it allows and what it does not

The Personal Importation Scheme lets individuals import a limited supply of certain medicines for personal use, up to three months, with a valid Australian prescription where one is required. Its limits matter more than its permissions:

  • It does not cover commercial supply. Importing unapproved goods to hold as stock is unlawful.
  • Some controlled substances need an import permit that a patient cannot obtain.
  • Products that are counterfeit or poorly labelled, for example showing only a code or omitting the active ingredient, can be seized and destroyed at the border.

The TGA's warning on importing unapproved peptide products, dated May 2026, says it continues to see peptides arriving through this scheme and describes many as unapproved, poorly labelled and outside Australian safety and quality standards.

Practical import checkpoints

  • Confirm the active ingredient and its schedule before ordering.
  • Check that a prescription exists where the scheme requires it.
  • Check that the label names the ingredient in full, not a code.
  • Expect seizure without compensation if documentation or labelling is inadequate.

For classification detail on shipments, our guide to HS codes for peptides in Australia covers how ABF and TGA read declarations.

Advertising and supply rules

The TGA states that advertising unapproved therapeutic goods to the public is illegal across websites, social media and influencer content. It uses website-blocking powers and works with the ABF. Its notice to promoters and suppliers points to heavy fines and possible criminal prosecution.

In June 2026 the regulator named unapproved peptides a priority focus area. Its response can include seizures, infringement notices and civil or criminal penalties.

This applies to:

  • Gyms, coaches and supplement shops recommending peptides for muscle gain, fat loss or recovery.
  • Social media creators describing benefits or dosing.
  • Wellness clinics promoting unapproved injectables.
  • Online stores making therapeutic claims.

Compounding and wellness clinics

Compounding lets a pharmacist prepare a medicine for a specific patient on a valid prescription. The TGA's April 2026 responsibilities notice addresses importing, compounding and supplying unapproved peptides. It reports concern about rising imports, supply, compounding and advertising.

The TGA also states that regulations were tightened in late 2024 to remove GLP-1 receptor agonist analogues from the compounding exemption, which makes large-scale compounding of those substances unlawful. Practitioners and pharmacies face scrutiny from both the TGA and Ahpra. The Conversation reported in July 2026 on clinics that labelled doses for a named person to supply unapproved peptides.

For readers asking what a legitimate prescription pathway looks like, see our peptide prescription requirements guide.

"Research use only": what the label does and does not do

This is the most common misunderstanding. A "research use only" (RUO) label does not change a product's regulatory status. It does not permit importation, and it does not exempt a product from advertising or supply laws if the product is used therapeutically. The TGA looks at what the product is and how it is promoted and used, not at the sticker.

That has two practical effects:

  • A consumer who buys an RUO vial to inject is using an unapproved therapeutic good, with none of the protections attached to approved medicines.
  • A supplier that hints at human use, through dosing talk, testimonials or body-goal marketing, creates the very problem the label was meant to avoid.

Legitimate laboratory work is a different activity: analytical standards, in vitro assays, cell culture and similar studies where nothing is given to people or animals outside an approved ethics framework. Institutions typically handle documentation, import conditions and ethics approvals through their own compliance offices. Our overview of peptide import permits in Australia and the documents labs attach to imports go through what customs look for. Examples of in-lab work are in Australian peptide research use.

Why the rules are strict: safety findings

The TGA has warned that unapproved peptides have been linked to severe allergic reactions, liver damage, systemic inflammatory response syndrome and local tissue damage from non-sterile injection, as set out in its enforcement media release. Reports to the regulator have also found imported "peptide" products containing unknown substances or no active ingredient.

Peptide-related safety concerns reported to TGA

Those are the stakes behind the purity argument. Verified identity and purity are a basic requirement for lab work, and they do nothing to make a product safe for injection into a person. Contamination is a separate risk, covered in our piece on peptide vial contamination.

Enforcement in practice

Enforcement is joint work between the TGA and the ABF, using intelligence-led screening. Recent examples:

Melbourne gym-goers should note the Victorian arrests: this is not a distant issue.

Our perspective

We supply research-grade peptides for laboratory use. We do not supply them for human use, and we do not present them as medicines or supplements. The TGA position is clear, and we state ours plainly.

What we focus on is what a laboratory can verify:

  • Each batch tested independently by HPLC and mass spectrometry.
  • Purity of ≥99% across the catalogue of 22+ compounds.
  • Traceable batch documentation.
  • Certificates of Analysis on request.

These controls address identity and purity, the two failures the TGA keeps finding in imported products. They do not change the legal status of a peptide, and we do not claim they do. A researcher should confirm institutional approvals and import conditions before ordering. Anyone looking for a product to inject should speak with a GP, who can explain the approved options and the SAS pathway.

— Tintastic

Research catalogue

For qualified researchers and institutions, our research catalogue covers Metabolic, Cognitive & Neuro, Tissue & Repair, Longevity, Cosmetic Science, Blends, Hormone & Reproductive, and Ancillaries & Reagents. Bulk and wholesale options are available. Orders are for laboratory research only. Documentation for each batch is available on request before you buy.

A short compliance checklist for labs

  1. Identify the substance and its Poisons Standard schedule.
  2. Confirm the study design is non-therapeutic and ethics-approved where required.
  3. Request the Certificate of Analysis and check HPLC and mass spec results against the label.
  4. Prepare import paperwork and an accurate description for customs.
  5. Store and handle per the supplier's reconstitution and storage notes.
  6. Keep records tying each batch to each experiment.

FAQ

Peptides are regulated as therapeutic goods. Approved ones are legal with a prescription. Many popular research peptides are unapproved, and it is unlawful to advertise, import for stock or supply them for therapeutic use. Some, such as BPC-157, are prescription-only under Schedule 4.

Can I import peptides for personal use?

The Personal Importation Scheme allows a limited supply of certain medicines with a valid Australian prescription. It does not cover unapproved goods for stock or supply, and poorly labelled or counterfeit items can be seized and destroyed. Check with your doctor before ordering anything.

No. The TGA states that the label does not change regulatory status or exempt a product from advertising and supply laws when it is used therapeutically. The label describes intended use for laboratory work, not a legal shield for human use.

Are peptides steroids?

No. Peptides are short amino acid chains, while anabolic steroids are a different chemical class. Both are targeted in TGA and ABF enforcement, and seizures often involve the two together.

Sources